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BAFF/BLyS Receptor 3 Binds the B Cell
Survival Factor BAFF Ligand through a Discrete
Surface Loop and Promotes Processing of NF-B2
and survival of peripheral B cells; mice lacking BAFF
display an almost total loss of follicular and marginal
zone B cells (Gross et al., 2001; Schiemann et al., 2001).
Transgenic mice overexpressing BAFF develop autoim-
mune disorders characterized by B cell hyperplasia and
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rheumatoid arthritis, and Sjo¨gren’s syndrome, where1 DNA Way
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and salivary/lacrymal glands, respectively, have ele-
vated levels of serum BAFF. Furthermore, BAFF levels
correlate with disease severity, consistent with a possi-Summary
ble role in the pathogenesis of these disabling maladies
(Cheema et al., 2001; Groom et al., 2002; Zhang et al.,The TNF-like ligand BAFF/BLyS is a potent survival
2001).factor for B cells. It binds three receptors: TACI, BCMA,
Of the three receptors for BAFF, only BR3 (also knownand BR3. We show that BR3 signaling promotes pro-
as BAFF-R) is specific; the other two, TACI and BCMA,cessing of the transcription factor NF-B2/p100 to
also bind the related ligand APRIL (Gross et al., 2000;p52. NF-B2/p100 cleavage was abrogated in B cells
Thompson et al., 2001; Yan et al., 2000, 2001a). Thefrom A/WySnJ mice possessing a mutant BR3 gene,
extracellular domain of TACI has a characteristic TNFR-but not in TACI or BCMA null B cells. Furthermore,
like structure encompassing two cysteine-rich domainswild-type mice injected with BAFF-neutralizing BR3-
(CRDs) that are the hallmark of the TNF receptor family.Fc protein showed reduced basal NF-B2 activation.
These approximately 40 residue pseudorepeats have aBR3-Fc treatment of NZB/WF1 mice, which develop a
distinct structure, typically characterized by three intra-fatal lupus-like syndrome, inhibited NF-B2 processing
chain disulfides involving six highly conserved cys-and attenuated the disease process. Since inhibiting
teines. BCMA is unusual in that it contains only a singlethe BR3-BAFF interaction has therapeutic ramifica-
canonical CRD. However, BR3 is even more divergenttions, the ligand binding interface of BR3 was investi-
in that its extracellular domain is composed of only agated and found to reside within a 26 residue core
partial CRD, containing four cysteine residues withdomain. When stabilized within a structured -hairpin
spacing distinct from other TNFR modules character-peptide, six of these residues were sufficient to confer
ized previously (Bodmer et al., 2002; Naismith andbinding to BAFF.
Sprang, 1998). Conventional members of the TNFR fam-
ily utilize two CRDs for binding ligand; contacts stemIntroduction
primarily from analogous loops from each CRD inter-
acting with two distinct surface patches on the ligandSurvival signals are critical for the proper development
(reviewed in Bodmer et al., 2002). Thus, how high-affinity
and maintenance of the immune system as they regulate
binding to BAFF is achieved by only a single, or partial,
the magnitude and duration of the immune response.
CRD, like that of BR3, is unclear. Recent crystal struc-
Many cytokines, including members of the TNF family, tures of BAFF reveal a trimeric TNF-like fold with several
such as CD40 ligand, have been shown to function as distinguishing features (Karpusas et al., 2002; Liu et al.,
potent survival factors for specific lymphoid populations 2002; Oren et al., 2002); however, no structure of any
(Locksley et al., 2001). BAFF (also known as BLyS, of the BAFF receptors has been described.
TALL-1, zTNF4, THANK, and TNFS 13B) (Moore et al., Characterization of naturally occurring mutations and
1999; Schneider et al., 1999), a recently defined member knockout mice have revealed components of the B cell
of the TNF family, is a homotrimeric type 2 transmem- survival pathway potentially engaged by BAFF. Since
brane protein expressed by macrophages, monocytes, A/WySnJ mice that possess a mutant BR3 display a
and dendritic cells. BAFF, like other members of the profound lack of B cells, akin to BAFF null mice, it has
TNF family, also exists in a soluble form following cleav- been hypothesized that BR3 must engage a B cell sur-
age from the cell surface by Furin-type proteases. It vival pathway (Gross et al., 2001; Schiemann et al., 2001;
shares most sequence similarity with APRIL, another Thompson et al., 2001; Yan et al., 2001a). Further, the
member of the TNF family, which is expressed by NF-B pathway is an attractive candidate for activation
lymphoid cells and at high levels by some tumor cells by BR3 because certain components are required for B
(Hahne et al., 1998). BAFF is critical for the development cell survival and maintenance (Caamano et al., 1998;
Franzoso et al., 1998). For example, IKK, one of two
catalytic subunits within the IB kinase complex, is re-5 Correspondence: dixit@gene.com (V.M.D.) or star@gene.com
(M.A.S.) quired for B cell maturation, formation of secondary
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Figure 1. Involvement of Endogenous BAFF/BR3 in Basal Processing of NF-B2 In Vivo
(A) Five C57BL/6 wild-type mice were injected intraperitoneally with PBS, 100 g TACI-Fc, or 100 g BR3-Fc daily for 5 days. 10 g pooled
splenic B cell lysate from each group was subjected to SDS-PAGE followed by Western blot analysis with anti-NF-B2 or anti- actin.
(B) Splenic B cells from PBS- or BR3-Fc-treated mice as described above were cultured with or without 1 g/ml recombinant BAFF for 24
hr. Thereafter, 10 g cultured B cell lysates were subjected to Western blot analysis with anti-NF-B2 or anti- actin.
(C) B cells were purified from pooled spleens of C57BL/6 (control), BCMA/ (Xu and Lam, 2001), TACI/ (Yan et al., 2001b), A/J, and A/WySnJ
mice. 10 g cell lysates were subjected to Western blot analysis with anti-NF-B2 or anti- actin.
lymphoid organs, and the inducible processing of the Herein, we show that the BAFF-BR3 interaction does
latent transcription factor NF-B2 (p100) to the active indeed promote processing of NF-B2/p100, both phys-
p52 NF-B subunit (Kaisho et al., 2001; Senftleben et iologically and in a murine model of lupus. Additionally,
al., 2001). Upon ectopic expression, an IKK-interacting we demonstrate that BR3 binds BAFF through a discrete
kinase, NIK, is also capable of triggering NF-B2/p100 surface loop; structural mimics of this loop could be
processing (Xiao et al., 2001). Indeed, processing by used to develop inhibitors to treat autoimmune dis-
ectopic NIK is inhibited in IKK-null lymphoid cells orders.
(Senftleben et al., 2001), consistent with IKK function-
ing downstream of NIK. In vitro studies suggest that
Results and DiscussionIKK can directly phosphorylate NF-B2/p100, leading
to ubiquitin-dependent generation of p52 (Senftleben et
BAFF/BR3 Signaling Promotes Processingal., 2001).
of NF-B2The only known activator of the NIK/IKK/NF-B2
Initially, we determined the impact of BAFF on NF-B2/pathway is the receptor for lymphotoxin- (LTR) (Yin
p100 processing in the whole animal. As reported pre-et al., 2001). Agonistic LTR antibodies induce NF-B2/
viously (Senftleben et al., 2001; Yamada et al., 2000),p100 processing in an NIK- and IKK-dependent manner
splenic B cells from untreated, naive mice display basal(Ghosh and Karin, 2002). LTR, however, is expressed
activation of the NIK/IKK/NF-B2 pathway as evi-on stromal cells and not on B lymphocytes, so the B
denced by the presence of p52. This signaling presum-cell ligand/receptor responsible for engaging the NIK/
ably results from the presence of an endogenous activa-IKK/NF-B2 pathway has been enigmatic. BAFF (Moore
tor, possibly BAFF, in the splenic microenvironment. Toet al., 1999; Schneider et al., 1999), as a potent survival
test this possibility, C57BL/6 mice were injected withfactor for B cells, is an attractive candidate along with
either purified recombinant TACI-Fc, which neutralizesits receptors TACI, BCMA, and BR3/BAFF-R (Gross et
both BAFF and APRIL, or BR3-Fc, which specificallyal., 2000, 2001; Schiemann et al., 2001; Thompson et
binds BAFF (Gross et al., 2000; Thompson et al., 2001;al., 2001; Yan et al., 2000, 2001a). Of the three receptors,
Yan et al., 2000, 2001a). In either case, generation of p52BR3 is most likely to signal B cell survival, as the BR3/
was diminished substantially, implying that endogenousBAFF-R mutant mouse strain A/WySnJ has defects in
BAFF is required for normal basal processing of NF-B2/B cell maturation and lymphoid organ architecture simi-
p100 in splenic B cells in vivo (Figure 1A). Nevertheless,lar to that seen in NIK (Yin et al., 2001)-, IKK (Kaisho et
BAFF may effect cleavage of NF-B2/p100 indirectly byal., 2001; Senftleben et al., 2001)- and NF-B2-deficient
inducing other cytokines that activate NF-B2/p100. Tomice (Caamano et al., 1998; Franzoso et al., 1998). In
eliminate any contribution from accessory cells, spleniccontrast, BCMA null mice have no discernable pheno-
B cells purified from mice treated with BR3-Fc (to reducetype (Schiemann et al., 2001; Xu and Lam, 2001), and
basal p52 generation) were cultured in the presence ofTACI null mice possess hyperresponsive B cells, spleno-
recombinant BAFF. Generation of p52 was augmentedmegaly, and increased Ig levels (Yan et al., 2001b), con-
sistent with TACI functioning as an inhibitory receptor. significantly in the presence of BAFF, consistent with
NF-B2 Activation by BR3
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Figure 2. BR3 Activation Is Sufficient for NF-
B2 Processing (p100 to p52)
(A) WEHI 231 murine B lymphoma cells were
infected retrovirally with vector alone (puro)
or encoding Edar-BR3, Edar-BR38, Edar-
BCMA, and Edar-TACI fusion constructs. The
transfectants were stained with FLAG-EDA-
A1 followed by anti-FLAG and PE-conjugated
anti-rabbit. After washing, cells were ana-
lyzed on a FACScan (Becton Dickinson) and
data processed using the CELLQuest pro-
gram (Becton Dickinson).
(B) WEHI 231 transfectants were cultured with
1 g/ml FLAG-EDA-A1 for 24 hr. 10 g cell
lysates of individual transfectants were sub-
jected to Western blot analysis with anti-NF-
B2 or anti- actin.
(C) WEHI 231 transfectants were cultured
with 1g/ml FLAG-EDA-A1 for indicated peri-
ods. Cell lysates (10 g) were subjected to
Western blot analysis with anti-phospho-IB-
 and anti- actin as a loading control.
BAFF acting directly on B cells to promote NF-B2 pro- et al., 2000; Schiemann et al., 2001; Thompson et al.,
2001; Yan et al., 2000, 2001a), we determined the contri-cessing (Figure 1B, right 2 lanes). BAFF also increased,
to a lesser extent, the amount of p52 in splenic B cells bution of each to NF-B2 processing. Similar levels of
processed p52 were found in B cells from controlfrom untreated wild-type mice (Figure 1B, left 2 lanes),
suggesting that endogenous levels of BAFF are not satu- C57BL/6, BCMA-, and TACI-deficient mice (Figure 1C).
In sharp contrast, no p52 was detected in B cells fromrating.
Since B cells express all three BAFF receptors (Gross the BR3 mutant A/WySnJ strain. These results con-
Immunity
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Figure 3. BR3 Crosslinking Can Rescue Anti-IgM-Induced Apoptosis
(A) WEHI 231 transfectants were cultured with or without 1 g/ml FLAG-EDA-A1  5 g/ml anti-FLAG Ab for 24 hr followed by coculture with
10 g/ml anti-IgM for 48 hr. Cells were then stained with FITC-AnnexinV (Becton Dickinson) and analyzed on a FACScan (Becton Dickinson).
Data represent the mean  SD of triplicate samples.
(B) Five 24-week-old NZB/WF1 mice were injected intraperitoneally with PBS or 100 g BR3-Fc fusion protein three times a week for 5 weeks.
10 g cell lysates from pooled splenic B cells of 54-week-old mice were subjected to Western blot analysis with anti-NF-B2 or anti- actin.
Age-matched C57BL/6 mice were used as control.
firmed a critical role for BR3 in BAFF-induced pro- generated an Edar receptor chimera lacking these eight
residues (Edar-BR38). This mutant receptor chimeracessing of NF-B2 in B cells.
To extend these in vivo observations, we determined failed to initiate p100 processing following EDA-A1 treat-
ment (Figure 2B), suggesting that the BR3 C terminusthe ability of individual BAFF receptors to induce NF-
B2 processing in vitro. A receptor chimera system was is critical for NF-B2 activation.
Most TNFR members can also activate the classicalused to stimulate each receptor specifically and to avoid
activating endogenous BAFF receptors. Thus, the extra- NF-B pathway (Ghosh and Karin, 2002). In this path-
way, IKK phosphorylates IB, resulting in ubiquitin-cellular ligand binding domains of BCMA, TACI, and
BR3 were replaced by the extracellular domain of the dependent degradation of IB and subsequent translo-
cation of the cytoplasmic p50/p65 transcriptional com-ectodysplasin receptor (Edar), a TNF receptor family
member expressed in developing skin but not in plex to the nucleus. To determine if any of the BAFF
receptors engaged this pathway, we examined the abil-lymphoid or hematopoietic tissues. Retroviral vectors
were used to express Edar-BCMA, Edar-TACI, and Edar- ity of individual BAFF receptors to induce phosphoryla-
tion of IB in WEHI231 transfectants. As shown in FigureBR3 in the murine B cell line WEHI 231. Expression of the
chimeric receptors was confirmed by flow cytometric 2C, all three BAFF receptors induced phospho-IB
(Ser32/36) within 10 min of activation. BR38 was unableanalysis of cells surface stained with the cognate ligand
for Edar, EDA-A1 (Figure 2A). Transfectants were cul- to induce IB phosphorylation, suggesting that the C-
terminal eight amino acid residues are important fortured in the presence of EDA-A1 to crosslink and acti-
vate the chimeric receptors and then examined for the engaging both the classical NF-B and the NF-B2 path-
ways. While these data indicate that all three BAFF re-presence of p52. As shown in Figure 2B, control puromy-
cin-resistant cells only expressed unprocessed NF-B2/ ceptors can activate the classical NF-B pathway, the
physiological significance of this is still unclear.p100. In contrast, p52 was induced in Edar-BR3
transfectants treated with EDA-A1. In keeping with the
in vivo data (Figure 1C), p52 was not generated in either BR3 Signaling Protects WEHI 231 Cells
from Anti-IgM-Induced ApoptosisEdar-BCMA or Edar-TACI transfectants, despite pro-
longed culture with EDA-A1 (Figure 2B). Taken together, Potentially harmful, autoreactive B cells are likely kept
in check by multiple mechanisms including deletionthese data suggest that BR3 alone can induce proteo-
lytic maturation of NF-B2 to p52. To mimic the inser- (Goodnow, 1992; Hertz and Nemazee, 1998; Klinman,
1996), but inappropriately high levels of a B cell survivaltional mutation that disrupts the eight C-terminal amino
acids of BR3 in A/WySnJ mice (Yan et al., 2001a), we factor, such as BAFF, may overcome such regulatory
NF-B2 Activation by BR3
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Figure 4. BR3-Fc Blocks Development of Lupus Disease in NZB/WF1 Mice
(A) 24-week-old female NZB/WF1 mice (12 mice per group) were injected intraperitoneally with PBS (open circles) or 100 g BR3-Fc (filled
circles) three times a week for 5 weeks. Mice were checked three times a week for morbidity. The number of mice surviving in each treatment
group is shown.
(B) Serum levels of circulating anti-dsDNA antibodies were checked monthly and are shown as OD450 values from an ELISA.
(C) Proteinuria was checked monthly and the percentage of mice in each group with levels greater than 300 mg/dL is shown.
(D) 54-week-old NZB/WF1 kidneys from both treatment groups. Arrows indicate fibrinoid necrosis and sclerosis prominent in affected glomeruli
accompanied by occasional crescent formation within the PBS-treated mice (left panel) compared to minimal glomerular changes in BR3-Fc-
treated animals (right panel).
mechanisms. Indeed, elevated BAFF serum levels have Blockade of BAFF Signaling in NZB/WF1 Mice
Abrogates p52 Generation and the Developmentbeen reported for patients with SLE (Zhang et al., 2001)
and Sjo¨gren’s syndrome (Groom et al., 2002), although of Spontaneous Lupus-like Disease
Given that BR3 signaling can protect WEHI 231 cellsa causal link is yet to be established. An in vitro model
for B cell negative selection is the induction of apoptosis from apoptosis induced by engagement of the B cell
receptor, inappropriate activation of the BAFF-BR3 axisin WEHI 231 cells by crosslinking anti-IgM antibody
(Benhamou et al., 1990; Hasbold and Klaus, 1990). We might contribute to the emergence of autoreactive B
cell clones that play a pathogenic role in autoimmunefound that prior engagement of Edar-BR3 with either
FLAG-EDA-A1 alone or FLAG-tagged ligand hyper- disease. To investigate this possibility, we studied NZB/
WF1 mice that develop spontaneous, fatal lupus-likecrosslinked with anti-FLAG antibody caused a marked
reduction in anti-IgM-induced apoptosis. In contrast, disease. At 22–24 weeks of age, NZB/WF1 mice exhib-
ited a slight but reproducible increase in the level of p52crosslinking Edar-BR38 failed to rescue the anti-IgM
stimulated cells (Figure 3A). Thus, the C terminus of BR3 in their B cells when compared to C57BL/6 mice (Figure
3B). This finding is consistent with the elevated levelsis critical for p52 generation, phospho-IB induction,
and the pro-survival role of BR3 in B cells. of BAFF in NZB/WF1 mice (Gross et al., 2000). To assess
Immunity
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Figure 5. Sequences of BR3 Variants and Structure of bhpBR3
(A) Amino acid sequences of BR3 variants used in this study.
(B and C) Three-dimensional structure of bhpBR3 determined by NMR spectroscopy. The backbone atoms of 20 models are shown superposed
with residue labels positioned in the direction of the side chain (B); one representative structure highlighting the BR3 turn residues (C) in the
same orientation as in B.
directly the contribution of BAFF to disease progression pathogenic role in the development of this autoimmune
disorder. In contrast, control-treated animals rapidly de-in NZB/WF1, we treated 24-week-old female animals
(12 per group) with a short 5 week course of BR3-Fc. veloped anti-dsDNA autoantibodies (Figure 4B) and suc-
cumbed to diffuse membranoproliferative glomerulone-This treatment dramatically attenuated the lupus-like
disease for the remaining 30 week length of the study: phritis characterized by mesangial proliferation and
inflammatory cell infiltrates. Fibrinoid necrosis and scle-B cell p52 levels were markedly reduced (Figure 3B),
there was a 100% survival rate (Figure 4A), and the rosis were prominent in affected glomeruli accompanied
by occasional crescent formation (Figure 4D). In sum,mice possessed fewer anti-double-stranded (ds) DNA
antibodies (Figure 4B). Renal damage was also less se- the data suggest that preventing the BAFF-BR3 interac-
tion may represent a viable therapeutic treatment forvere as evidenced by diminished proteinuria (Figure 4C)
and only mild glomerular changes on renal histology lupus.
(Figure 4D). Previous studies have shown that treatment
with TACI-Fc, which binds both BAFF and APRIL, also The BAFF Binding Site within BR3 Is Contained
within a 26 Residue Core Domainsuppresses proteinuria but does not block the genera-
tion of anti-dsDNA antibodies (Gross et al., 2000). It is As a first step toward developing agents to disrupt the
BAFF-BR3 interaction, an NMR analysis of the extracel-not clear why BR3-Fc, which exclusively binds BAFF
(Thompson et al., 2001; Yan et al., 2001a), should so lular ligand binding domain of BR3 was performed. In-
triguingly, only the central one-third of the proteinpotently suppress autoantibody titers, but it may relate
to pharmacokinetic differences or a greater potency in adopts a stable structure in solution; this core is stabi-
lized by two disulfide bonds connecting Cys19/Cys32neutralizing bioavailable BAFF.
To assess the effect of initial BR3-Fc treatment on and Cys24/Cys35 (M.A.S., J.Y., and W.J. Fairbrother,
unpublished data). Consequently, a 26 residue miniBR3long-term leukocyte counts, peripheral blood was ana-
lyzed at the time of sacrifice. Leukocyte counts including peptide was synthesized, incorporating the 1:3, 2:4 di-
sulfide-bonding pattern, and characterized structurallyB cell numbers were within normal limits at the end of
the study. Thus, the initial BR3-Fc treatment may have (Figure 5A). Indeed, NMR spectra of miniBR3 indicated
that this peptide adopts essentially the same structureeliminated or silenced B cell populations that play a
NF-B2 Activation by BR3
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Figure 6. Binding of BR3 Variants to BAFF
(A) Competitive displacement of biotinylated miniBR3 measured by ELISA (see Experimental Procedures). Data are shown for BR3 extracellular
domain (filled squares), miniBR3 (open squares), and bhpBR3 (filled circles). IC50 values from the fitted curves are 70 nM, 65 nM, and 15 M,
respectively.
(B) COS 7 cells transfected with BAFF were stained with BR3-Fc or BR3 A26/A28-Fc followed by Cy3-labeled anti-human IgG Fc.
(C) Splenic B cells from BR3-Fc-treated mice were cultured for 24 hr in the presence or absence of recombinant BAFF (2 nM), which had
been preincubated for 30 min with bhpBR3 (60 M) or a control hairpin peptide composed of an unrelated turn sequence in the same bhp
scaffold (bhpC, 60 M). Thereafter, B cell lysates (10 g) were subjected to Western blot analysis with anti-NF-B2 or anti- actin.
as in the context of the full-length protein (not shown). eate the BAFF binding portion of BR3. In crystal struc-
tures of other TNF-like ligand/receptor complexes, aImportantly, miniBR3 also binds with the same affinity
as full-length BR3 to BAFF (70 nM IC50; Figure 6A). receptor loop analogous to BR3 residues 26DLLVRH31
is involved in forming direct contacts with the ligandGiven that high-affinity BAFF binding was contained
within a 26 residue core, we attempted to further delin- (Bodmer et al., 2002, and references therein). Intrigu-
Immunity
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Experimental Proceduresingly, all three BAFF receptors share the short motif
“DxL” at the beginning of this loop (see below). The
Isolation and Culture of B Cellsimportance of the conserved motif for BAFF binding
Splenic B cells were isolated using MACS beads (Miltenyi). Recov-
was tested by site-directed mutagenesis. As shown in ered cells were 96% B220	IgM	 B cells. In some experiments,
Figure 6B, replacement of the two invariant loop resi- freshly isolated B cells were further cultured with 1 g/ml recombi-
nant BAFF (Yan et al., 2001a) for 24 hr.dues of BR3-Fc (D26 and L28) with alanine resulted
in complete loss of binding to BAFF, confirming the
Western Blot Analysisimportance of the loop in BAFF recognition.
Cell lysis and immunoblotting were performed as described (HumkeIn the context of both full-length and miniBR3, NMR et al., 2000). Anti-NF-B2 (Santa Cruz) was used to detect p100
analysis suggested that the critical loop sequence and p52. Phospho-IB--specific antibody (Ser32/36, Cell Signaling)
26DLLVRH31 presents a type I  turn centered at L28/V29 was used to detect phospho-IB-.
with potential for backbone hydrogen-bonding between
Retroviral Construction and InfectionAsp26 and His31. Thus, in order to test whether this
Extracellular domains of BCMA (1-42), TACI (1-114), and BR3 (1-loop might be sufficient for binding, we synthesized a
55) were replaced by Edar (1-182) by recombinant PCR. Resulting
12 residue peptide in which the six residues from BR3 cDNAs were subcloned into a puromycin-selectable retrovirus vec-
were embedded within a disulfide-bonded  hairpin tor. Production and infection of retrovirus were performed as de-
(bhp) scaffold (Figure 5A). Previously, we have shown scribed elsewhere (Humke et al., 2000). WEHI 231 cells stably ex-
pressing chimeric receptors were selected using 1g/ml puromycin.that the strong strand-strand interactions in these scaf-
folds can structure a variety of  turns (Cochran et al.,
NZB/WF1 Lupus Mice Studies2001; S.J. Russell, T. Blandl, N.J. Skelton, and A.G.C.,
Female NZB/WF1 mice were purchased from Jackson. Proteinuria
unpublished data; Russell and Cochran, 2000). levels were monitored by Uristix (Ames). Anti-dsDNA antibody titers
The peptide bhpBR3 adopts a remarkably stable con- in the serum were measured using poly L-lysine/poly dAdT (Sigma)
formation in solution as indicated by a high degree of coated plates and detected with HRP-conjugated goat anti-mouse
IgG antibody. In some experiments, kidneys from 54-week old NZB/chemical shift dispersion, extreme values for many of
WF1 mice were fixed in 10% neutral-buffered formalin and embed-the backbone and side chain coupling constants, and
ded in paraffin. Three micron thick sections stained with hematoxylina large number of long-range NOEs present in its NMR
and eosin were examined by light microscopy.
spectra (see supplemental table S1 at http://www.
immunity.com/cgi/content/full/17/4/515/DC1). The Protein Production
three-dimensional structure of bhpBR3 consists of a  The extracellular domain of BR3 was subcloned into the pET32a
expression vector (Novagen), creating a fusion with an N-terminalhairpin in which the BR3 turn sequence adopts the type
thioredoxin (TRX)-His-tag followed by an enterokinase protease site.I  turn structure, as expected, with Arg30 adopting a
E. coli BL21(DE3) cells (Novagen) were grown at 30
C and protein
positive φ angle and the side chains of the invariant expression was induced with IPTG. TRX-BR3 was purified over an
Asp26 and Leu28, as well as those of Val29 and His31, Ni-NTA column (Qiagen), eluted with an imidazole gradient, and
projecting on one face of the  turn (Figures 5B and 5C). cleaved with enterokinase (Novagen). BR3 was then purified over
an S-Sepharose column, refolded overnight in PBS (pH 7.8), in theIf BR3 binds BAFF using interactions homologous to
presence of 3 mM oxidized and 1 mM reduced glutathione, dialyzedthose observed for TNFR and DR5 (Hymowitz et al.,
against PBS, repurified over a MonoS column, concentrated, and1999), then one would expect this face (the “bottom”
dialyzed into PBS.
face of the turn shown in Figure 5C) to contact BAFF.
Because bhpBR3 structurally mimics the BR3 turn, Peptide Synthesis
we tested whether it could compete with miniBR3 for MiniBR3 and bhpBR3 were synthesized as C-terminal amides on a
Pioneer peptide synthesizer (PE Biosystems) using standard Fmocbinding to BAFF (Figure 6A). Remarkably, the 12 residue
chemistry. For miniBR3, the side chain thiols of cysteines 19 andpeptide blocked binding of the larger core domain (IC50
32 were protected as the trifluoroacetic acid (TFA)-stable acetami-15 M), indicating that the critical binding determinants
domethyl (Acm) derivatives. Peptides were cleaved from resin by
do indeed reside in the six residue loop shown in Figure treatment with 5% triisopropyl silane in TFA for 1.5–4 hr at room
5C. Finally, we tested whether bhpBR3 could function temperature. After removal of TFA by rotary evaporation, peptides
were precipitated by addition of ethyl ether, then purified by re-in a bioassay: bhpBR3, but not a control hairpin peptide,
versed-phase HPLC (acetonitrile/H2O/0.1% TFA). Peptide identityblocked BAFF-mediated NF-B2/p52 induction in pri-
was confirmed by electrospray mass spectrometry. BhpBR3 wasmary B cells (Figure 6C).
converted to the cyclic disulfide by dropwise addition of a saturated
Our finding that a turn structure from BR3 has signifi- solution of I2 (in acetic acid) to HPLC fractions. After lyophilization,
cant affinity for BAFF has implications for recognition the oxidized peptide was purified by HPLC. HPLC fractions con-
taining reduced miniBR3 were adjusted to a pH of 9 with NH4OH;of BAFF by its other receptors. TACI and BCMA share
the disulfide between cysteines 24 and 35 was then formed byhomologous sequences in this loop region that would
addition of a small excess of K3Fe(CN)6, and the oxidized peptidebe expected to adopt a similar turn conformation to that
purified by HPLC. Acm groups were removed (with concomitant
in BR3 (DSLLHA, DPLLGT, and DHLLRD, for BCMA and formation of the second disulfide) by treatment of the HPLC eluate
CRDs 1 and 2 of TACI, respectively). Therefore, the inter- with a small excess of I2 over 4 hr. The progress of the oxidation
actions of this turn with ligand will likely be a conserved was monitored by analytical HPLC, and the final product was again
purified by HPLC. MiniBR3 was amino-terminally biotinylated whilefeature of all BAFF/receptor complexes. The surprising
on resin, then cleaved and purified exactly as described above foridentification of such a focused recognition epitope will
the unmodified peptide.provide the framework for developing small-molecule
peptidomimetic inhibitors of the BAFF-BR3 interaction; NMR Spectroscopy
these inhibitors may have therapeutic potential in the Two-dimensional (2D) NMR experiments were acquired and ana-
lyzed as described (Starovasnik et al., 1996) using a Bruker DRX-treatment of autoimmune diseases such as lupus.
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the allowed, and 4% in the generously allowed regions ofφ space)
tion coefficients from amino acid sequence data. Anal. Biochem.
(Laskowski et al., 1993). The structure of bhpBR3 will be available
182, 319–326.
from the RCSB Protein Data Bank (ID code 1MPV).
Goodnow, C.C. (1992). Transgenic mice and analysis of B-cell toler-
ance. Annu. Rev. Immunol. 10, 489–518.Competitive Displacement ELISA
Groom, J., Kalled, S.L., Cutler, A.H., Olson, C., Woodcock, S.A.,Nunc Maxisorp 96-well plates were coated overnight at 4
C with
Schneider, P., Tschopp, J., Cachero, T.G., Batten, M., Wheway, J.,100 l of a 2 g/ml solution of BAFF in carbonate buffer (pH 9.6).
et al. (2002). Association of BAFF/BLyS overexpression and alteredThe plate was washed with PBS and blocked with 1% skim milk in
B cell differentiation with Sjo¨gren’s syndrome. J. Clin. Invest. 109,PBS. Serial dilutions of BR3 variants were prepared in PBS/0.05%
59–68.Tween 20 containing 3 ng/ml biotinylated miniBR3. After washing
with PBS/Tween, 100 l/well of each dilution was transferred and Gross, J.A., Johnston, J., Mudri, S., Enselman, R., Dillon, S.R., Mad-
incubated for 1 hr at room temperature. The plate was washed with den, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al.
PBS/Tween and incubated for 15 min with 100 l/well of 0.1 U/ml (2000). TACI and BCMA are receptors for a TNF homologue impli-
Streptavidin-POD (Boehringer Mannheim) in PBS/Tween. After cated in B-cell autoimmune disease. Nature 404, 995–999.
washing with PBS/Tween followed by PBS, the plate was incubated Gross, J.A., Dillon, S.R., Mudri, S., Johnston, J., Littau, A., Roque,
for 5 min with 100 l PBS substrate solution containing 0.8 mg/ml R., Rixon, M., Schou, O., Foley, K.P., Haugen, H., et al. (2001). TACI-
OPD (Sigma) and 0.01% H2O2. The reaction was quenched with 100 Ig neutralizes molecules critical for B cell development and autoim-
l/well 1 M H3PO4 and the plate read at 490 nm. IC50 values were mune disease, impaired B cell maturation in mice lacking BLyS.
determined by a four-parameter fit of the competitive displacement
Immunity 15, 289–302.
ELISA signal. The concentrations of initial stock solutions of bhpBR3
Hahne, M., Kataoka, T., Schroter, M., Hofmann, K., Irmler, M.,were determined spectrophotometrically as described (Gill and von
Bodmer, J.L., Schneider, P., Bornand, T., Holler, N., French, L.E., etHippel, 1989), while those of miniBR3 and BR3 extracellular domain
al. (1998). APRIL, a new ligand of the tumor necrosis factor family,were determined by quantitative amino acid analysis.
stimulates tumor cell growth. J. Exp. Med. 188, 1185–1190.
BR3-Fc Staining of BAFF-Transfected COS7 Cells Hasbold, J., and Klaus, G.G. (1990). Anti-immunoglobulin antibodies
Mutations that disrupt residues within the 26DLLVRH31 loop induce apoptosis in immature B cell lymphomas. Eur. J. Immunol.
(D26→A26 and L28→A28) were introduced into BR3-Fc cDNA (Yan 20, 1685–1690.
et al., 2001a) by PCR. C0S7 cells transfected with BAFF were stained Hertz, M., and Nemazee, D. (1998). Receptor editing and commit-
with 1 g/ml BR3-Fc or BR3 A26/A28-Fc. Cells were washed and ment in B lymphocytes. Curr. Opin. Immunol. 10, 208–213.
fixed, and bound receptor detected with Cy3-labeled anti-human
Humke, E.W., Shriver, S.K., Starovasnik, M.A., Fairbrother, W.J.,IgG Fc (Jackson).
and Dixit, V.M. (2000). ICEBERG: a novel inhibitor of interleukin-1
generation. Cell 103, 99–111.Acknowledgments
Hymowitz, S.G., Christinger. H.W., Fuh, G., Ultsch, M., O’Connell,
M., Kelley, R.F., Ashkenazi, A., and de Vos, A.M. (1999). TriggeringWe thank Kim Newton, Karen O’Rourke, John Ridgway Brady, Ingrid
cell death: the crystal structure of Apo2L/TRAIL in a complex withWertz, Robert Kelley, Wayne Fairbrother, Sarah Hymowitz, and
death receptor 5. Mol. Cell 4, 563–571.members of the Dixit lab for encouragement and discussion; Kimi-
nori Hasegawa for isolation of B cells; Marjie Van Hoy and Joel Kaisho, T., Takeda, K., Tsujimura, T., Kawai, T., Nomura, F., Terada,
Morales for necropsy support; Linda Hall for histochemistry; Shawn N., and Akira, S. (2001). IB kinase  is essential for mature B cell
Salesky and Charles Jones III for paraffin embedding and sectioning; development and function. J. Exp. Med. 193, 417–426.
Hong Liu for amino acid analysis; Tamas Blandl for the bhpC pep- Karpusas, M., Cachero, T.G., Qian, F., Boriack-Sjodin, A., Mullen,
tide; and Kong-Peng Lam for BCMA/ mice. C., Strauch, K., Hsu, Y.M., and Kalled, S.L. (2002). Crystal structure
of extracellular human BAFF, a TNF family member that stimulates
Received: August 23, 2002 B lymphocytes. J. Mol. Biol. 315, 1145–1154.
Revised: September 11, 2002
Khare, S.D., Sarosi, I., Xia, X.Z., McCabe, S., Miner, K., Solovyev,
I., Hawkins, N., Kelley, M., Chang, D., Van, G., et al. (2000). SevereReferences
B cell hyperplasia and autoimmune disease in TALL-1 transgenic
mice. Proc. Natl. Acad. Sci. USA 97, 3370–3375.Benhamou, L.E., Cazenave, P.A., and Sarthou, P. (1990). Anti-immu-
Klinman, N.R. (1996). The “clonal selection hypothesis” and currentnoglobulins induce death by apoptosis in WEHI-231 B lymphoma
cells. Eur. J. Immunol. 20, 1405–1407. concepts of B cell tolerance. Immunity 5, 189–195.
Immunity
524
Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M.P. induced NF-B transcriptional activity in NIK-deficient mice. Sci-
ence 291, 2162–2165.(1993). A program to check the stereochemical quality of protein
structures. J. Appl. Crystallogr. 26, 283–291. Zhang, J., Roschke, V., Baker, K.P., Wang, Z., Alarcon, G.S., Fessler,
B.J., Bastian, H., Kimberly, R.P., and Zhou, T. (2001). Cutting edge:Liu, Y., Xu, L., Opalka, N., Kappler, J., Shu, H.B., and Zhang, G.
a role for B lymphocyte stimulator in systemic lupus erythematosus.(2002). Crystal structure of sTALL-1 reveals a virus-like assembly
J. Immunol. 166, 6–10.of TNF family ligands. Cell 108, 383–394.
Locksley, R.M., Killeen, N., and Lenardo, M.J. (2001). The TNF and
Accession NumberTNF receptor superfamilies: integrating mammalian biology. Cell
104, 487–501.
The structure of bhpBR3 will be available from the RCSB ProteinMackay, F., Woodcock, S.A., Lawton, P., Ambrose, C., Baetscher,
Data Bank under ID code 1MPV.M., Schneider, P., Tschopp, J., and Browning, J.L. (1999). Mice
transgenic for BAFF develop lymphocytic disorders along with auto-
immune manifestations. J. Exp. Med. 190, 1697–1710.
Moore, P.A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D.W., Feng,
P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999).
BLyS: member of the tumor necrosis factor family and B lymphocyte
stimulator. Science 285, 260–263.
Naismith, J.H., and Sprang, S.R. (1998). Modularity in the TNF-recep-
tor family. Trends Biochem. Sci. 23, 74–79.
Oren, D.A., Li, Y., Volovik, Y., Morris, T.S., Dharia, C., Das, K., Galper-
ina, O., Gentz, R., and Arnold, E. (2002). Structural basis of BLyS
receptor recognition. Nat. Struct. Biol. 9, 288–292.
Russell, S.J., and Cochran, A.G. (2000). Designing stable -hairpins:
energetic contributions from cross-strand residues. J. Am. Chem.
Soc. 122, 12600–12601.
Schiemann, B., Gommerman, J.L., Vora, K., Cachero, T.G., Shulga-
Morskaya, S., Dobles, M., Frew, E., and Scott, M.L. (2001). An essen-
tial role for BAFF in the normal development of B cells through a
BCMA-independent pathway. Science 293, 2111–2114.
Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J.L.,
Holler, N., Ambrose, C., Lawton, P., Bixler, S., Acha-Orbea, H., et
al. (1999). BAFF, a novel ligand of the tumor necrosis factor family,
stimulates B cell growth. J. Exp. Med. 189, 1747–1756.
Senftleben, U., Cao, Y., Xiao, G., Greten, F.R., Krahn, G., Bonizzi,
G., Chen, Y., Hu, Y., Fong, A., Sun, S.C., et al. (2001). Activation by
IKKof a second, evolutionary conserved, NF-B signaling pathway.
Science 293, 1495–1499.
Starovasnik, M.A., Skelton, N.J., O’Connell, M.P., Kelley, R.F., Reilly,
D., and Fairbrother, W.J. (1996). Solution structure of the E-domain
of Staphylococcal protein A. Biochemistry 35, 15558–15569.
Thompson, J.S., Bixler, S.A., Qian, F., Vora, K., Scott, M.L., Cachero,
T.G., Hession, C., Schneider, P., Sizing, I.D., Mullen, C., et al. (2001).
BAFF-R, a newly identified TNF receptor that specifically interacts
with BAFF. Science 293, 2108–2111.
Xiao, G., Harhaj, E.W., and Sun, S.C. (2001). NF-B-inducing kinase
regulates the processing of NF-B2 p100. Mol. Cell 7, 401–409.
Xu, S., and Lam, K.P. (2001). B-cell maturation protein, which binds
the tumor necrosis factor family members BAFF and APRIL, is dis-
pensable for humoral immune responses. Mol. Cell. Biol. 21, 4067–
4074.
Yamada, T., Mitani, T., Yorita, K., Uchida, D., Matsushima, A., Iwa-
masa, K., Fujita, S., and Matsumoto, M. (2000). Abnormal immune
function of hemopoietic cells from alymphoplasia (aly) mice, a natu-
ral strain with mutant NF-B-inducing kinase. J. Immunol. 165,
804–812.
Yan, M., Marsters, S.A., Grewal, I.S., Wang, H., Ashkenazi, A., and
Dixit, V.M. (2000). Identification of a receptor for BLyS demonstrates
a crucial role in humoral immunity. Nat. Immunol. 1, 37–41.
Yan, M., Brady, J.R., Chan, B., Lee, W.P., Hsu, B., Harless, S., Can-
cro, M., Grewal, I.S., and Dixit, V.M. (2001a). Identification of a novel
receptor for B lymphocyte stimulator that is mutated in a mouse
strain with severe B cell deficiency. Curr. Biol. 11, 1547–1552.
Yan, M., Wang, H., Chan, B., Roose-Girma, M., Erickson, S., Baker,
T., Tumas, D., Grewal, I.S., and Dixit, V.M. (2001b). Activation and
accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2,
638–643.
Yin, L., Wu, L., Wesche, H., Arthur, C.D., White, J.M., Goeddel, D.V.,
and Schreiber, R.D. (2001). Defective lymphotoxin- receptor-
